NCT06419374

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2024-05-24Est. Completion: 2028-06-30

Enrollment target: 1,800 participants

Locations

89bio Clinical Study Site, Birmingham, Alabama, United States
89bio Clinical Study Site, Homewood, Alabama, United States
89bio Clinical Study Site, Chandler, Arizona, United States
89bio Clinical Study Site, Flagstaff, Arizona, United States
89bio Clinical Study Site, Peoria, Arizona, United States
89bio Clinical Study Site, Phoenix, Arizona, United States
89bio Clinical Study Site, Sun City, Arizona, United States
89bio Clinical Study Site, Tucson, Arizona, United States
89bio Clinical Study Site, Tucson, Arizona, United States
89bio Clinical Study Site, Tucson, Arizona, United States
89bio Clinical Study Site, Little Rock, Arkansas, United States
89bio Clinical Study Site, North Little Rock, Arkansas, United States
89bio Clinical Study Site, Camarillo, California, United States
89bio Clinical Study Site, Canoga Park, California, United States
89bio Clinical Study Site, Coronado, California, United States
89bio Clinical Study Site, Fountain Valley, California, United States

Other microbiome trials you might be interested in

Evaluating the Pharmacokinetics and Safety of MiricorilantPhase 1Completed

Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed …

San Antonio, United StatesCompleted Sep 22, 2026

View Trial →

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisPhase 3Recruiting

Metabolic Dysfunction Associated Steatohepatitis

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic s…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.